| abstract |
Novel antibodies directed against Dual Ig domain containing cell adhesion molecule (DICAM) are described. These anti-DICAM antibodies are capable of detecting DICAM by Western blot and/or flow cytometry, blocking the interaction between DICAM and its ligand α Vβ3 integrin, and/or blocking the migration of inflammatory cytokine-secreting T H 17 lymphocytes across the blood brain barrier. Uses of these antibodies or compositions comprising same for the diagnosis, prevention and/or treatment of autoimmune/inflammatory conditions, such as neuroinflammatory conditions, and for the targeting, identification and selection of inflammatory cytokine-secreting T H 17 lymphocytes or precursor thereof are also disclosed. |